UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine
ISSN 2079-0325(p)
DOI 10.36927/2079-0325
Home » Archive of numbers » 2024 » Volume 32, issue 2 (119) » INNOVATIVE OPPORTUNITIES OF PHARMAKOTHERAPY OF GENERALIZED ANXIETY DISORDER

INNOVATIVE OPPORTUNITIES OF PHARMAKOTHERAPY OF GENERALIZED ANXIETY DISORDER

Authors

Type of Article

  • Scientific Article

In the Section

  • DIAGNOSTICS AND THERAPY OF MENTAL AND BEHAVIORAL DISORDERS

Key words

Index UDK:
  • 616.89-008.454:615.03:330.341.1

Abstract

The work shows the actual problem and proven effectiveness of treatment of generalized anxiety disorder (GAD), including its modern methods. There was an open-label, 6-week study of the efficacy, safety, and tolerability of opipramol dihydrochloride 200 mg/day to evaluate an innovative method of treatment the patients with GAD. The conducted study demonstrates the rapid and powerful anxiolytic effect of opipramol dihydrochloride in the treatment of general, mental and somatic anxiety in patients with GAD. Opipramol dihydrochloride demonstrates a reliable fast and strong vegetative-stabilizing effect in the treatment of vegetative and somatic symptoms from the cardiovascular, gastrointestinal, respiratory, genitourinary and neurological systems in the patients with GAD. Opipramol dihydrochloride is the drug of first choice in the treatment of GAD and an alternative treatment for anxiety disorders.

Pages

  • 32-37

Year / Issue

Download PDF

References

  1. Roberge P, Normand-Lauzière F, Raymond I, Luc M, Tanguay-Bernard MM, Duhoux A, Bocti C, Fournier L. Generalized anxiety disorder in primary care: mental health services use and treatment adequacy. BMC Fam Pract. 2015 Oct 22;16:146. doi: https://doi.org/10.1186/s12875-015-0358-y. PMID: 26492867; PMCID: PMC4618956.
  2. Rosellini AJ, Bourgeois ML, Correa J, Tung ES, Goncharenko S, Brown TA. Anxious distress in depressed outpatients: Prevalence, comorbidity, and incremental validity. J Psychiatr Res. 2018 Aug;103:54-60. doi: https://doi.org/10.1016/j.jpsychires.2018.05.006. Epub 2018 May 8. PMID: 29778071; PMCID: PMC8903047.
  3. Preti A, Vrublevska J, Veroniki AA, Huedo-Medina TB, Fountoulakis KN. Prevalence, impact and treatment of generalised anxiety disorder in bipolar disorder: a systematic review and meta-analysis. Evid Based Ment Health. 2016;19(3):73–81. doi: https://doi.org/10.1136/eb-2016-102412.
  4. Latas M, Trajković G, Bonevski D, Naumovska A, Vučinić Latas D, Bukumirić Z, Starčević V. Psychiatrists’ treatment preferences for generalized anxiety disorder. Hum Psychopharmacol. 2018 Jan; 33(1). doi: https://doi.org/10.1002/hup.2643. Epub 2017 Dec 20. PMID: 29266492.
  5. Gomez AF, Barthel AL, Hofmann SG. Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. Expert Opin Pharmacother. 2018;19(8):883–894. doi: https://doi.org/10.1080/14656566.2018.1472767.
  6. Perna G, Alciati A, Riva A, Micieli W, Caldirola D. Longterm pharmacological treatments of anxiety disorders: an updated systematic review. Curr Psychiatry Rep. 2016;18(3):23. doi: https://doi.org/10.1007/s11920-016-0668-3.
  7. Fagan H., Baldwin D. Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions. Expert Rev Neurother. 2023 Jun;23(6):535-548. doi: https://doi.org/10.1080/14737175.2023.2211767. Epub 2023 May 15.
  8. Jaracz J., Rybakowski J. Pharmacological and clinical properties of opipramol in the light of new studies. Farmakoter Psychiat Neurol 2003; 4:115-121.
  9. Müller W. E., Siebert B., Holoubek G. Neuropharmacology of the anxiolytic drug opipramol, a sigma site ligand. Pharmacopsychiatry 2004; 37(Suppl 3):S189-197. doi: https://doi.org/10.1055/s-2004-832677. PMID: 15547785.
  10. Peng R. Sigma-1 Receptors in Depression: Mechanism and Therapeutic Development. Front. Pharmacol. 2022 Jun 16;13:925879. doi: https://doi.org/10.3389/fphar.2022.925879. PMID: 35784746; PMCID: PMC9243434.
  11. Krupka-Matuszczyk I. Opipramol: drug traditionally used in the treatment of anxiety and depression. Case studies. Rev Clin Neuropsychiatry, 2012; 4:131-134. doi: https://doi.org/10.1002/14651858. CD010628.pub2.
  12. Ren  P., Wang J., Li N., Li G., Ma H., Zhao Y. Sigma-1 Receptors in Depression: Mechanism and Therapeutic Development Frontiers in Pharmacology, 2022; 13:879-925. doi: https://doi.org/10.3389/fphar.2022.925879.
  13. Dursun H., Albayrak F., Bilici M., Koc F., Candar T. Gastroprotective and antioxidant effects of opipramol on indomethacin-induced ulcers in rats. Yakugaku Zasshi, 2009; 129:861-9. doi: https://doi.org/10.1248/yakushi.129.861. PMID: 19571522.
  14. Mohapatra S., Rath N. M., Agrawal A. Opipramol: a novel drug. Delhi Psychiatry Journal, 2013; 16:409–411.
  15. Generalised anxiety disorder and panic disorder in adults: management. NICE, 2020. www.nice.org.uk/guidance/cg113.
  16. Bandelow B., Werner AM, Kopp I, Rudolf S, Wiltink J, Beutel ME. The German Guidelines for the treatment of anxiety disorders: first revision. Eur Arch Psychiatry Clin Neurosci. 2022 Jun;272(4):571-582. doi: https://doi.org/10.1007/s00406-021-01324-1. Epub 2021 Oct 5. PMID: 34609587; PMCID: PMC8490968.
  17. Möller HJ, Volz HP, Reimann IW & Stoll KD: Opipramol for the treatment of generalized anxiety disorder: a placebocontrolled trial including an alprazolam-treated group. J Clin Psychopharmacol, 2001 Feb;21(1):59-65. doi: https://doi.org/10.1097/00004714-200102000-00011. PMID: 11199949.
  18. Święcicki Ł: Practical aspects of  pharmacotherapy of anxiety — is there a place for opipramol. Psychiatria, 2013; 10:63-66.
  19. Bandelow B., Boerner R.J., Kasper S., Linden M., Wittchen H.U., Müller W.E. The diagnosis and treatment of generalized anxiety disorder. Dtsch Arztebl Int, 2013; 110(17)300-10. doi: https://doi.org/10.3238/arztebl.2013.0300.
  20. Vaccarino AL, Evans KR, Sills TL, Kalali AH. Symptoms of  anxiety in  depression: assessment of  item performance of the Hamilton Anxiety Rating Scale in patients with depression. Depression & Anxiety, 2008;25(12):1006-13. doi: https://doi.org/10.1002/ da.20435. PMID: 18800370.
  21. ICD-11 for Mortality and Morbidity Statistics (ICD-11 MMS) (Version : 01/2023). URI: https://icd.who.int/browse11/l-m/en.

Journal’s Indexing:

UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine

ДУ «ІНПН імені
П.В. ВОЛОШИНА
НАМН УКРАЇНИ»